-
Sensview Secures Tens of Millions in Series A+ Funding for X-Ray Detector Tech
•
Sensview, a developer of solid-state imaging chips and detector module products based in Chengdu, has reportedly secured tens of millions of renminbi in a Series A+ financing round. The round was led by Matrix Partners, with contributions from Suzhou Industrial Park Zhongyuan Naxing Venture Capital and Leli Capital, as well…
-
Nanjing Enrui Kainuo Biotechnology Secures Pre-Series A Funding for Cell Therapy Development
•
Nanjing Enrui Kainuo Biotechnology Co., Ltd, a China-based cell therapy developer, has reportedly raised tens of millions of renminbi in a pre-Series A financing round. The round was led by Watere Capital, with participation from Future Invest. The funds raised will be directed towards IND filings, advancing the product pipeline,…
-
Shenzhen Salubris Pharmaceuticals Receives FDA Clearance for SAL0119 Clinical Trial
•
Shenzhen Salubris Pharmaceuticals Co., Ltd (SHE: 002294), a Chinese pharmaceutical company, has announced that it has received clinical clearance from the US Food and Drug Administration (FDA) for its small molecule pipeline candidate, SAL0119. The upcoming trial will evaluate SAL0119 as a potential treatment for rheumatoid arthritis, ankylosing spondylitis (AS),…
-
Bio-Thera Solutions Receives NMPA Approval for CTLA-4 and PD-1 Inhibitor Combo Study
•
China-based Bio-Thera Solutions Ltd (SHA: 688177) has announced that it has received approval from China’s National Medical Products Administration (NMPA) to initiate a clinical study for its BAT4706, a cytotoxic T-lymphocyte antigen 4 (CTLA-4) monoclonal antibody (mAb), in combination with its programmed death-1 (PD-1) inhibitor BAT1308. The study will focus…
-
Shanghai Pharmaceuticals Gets NMPA Green Light for Recombinant Human Adenovirus Type 5 Trial
•
Shanghai Pharmaceuticals (HKG: 2607; SHA: 601607), a leading pharmaceutical company in China, has announced that it has received clinical trial approval from China’s National Medical Products Administration (NMPA) for its recombinant human adenovirus type 5 in the treatment of malignant ascites. The filing for this trial was accepted for review…
-
China’s NHC Issues Guidelines to Enhance Clinical Department Capacities for Serious Diseases
•
The National Health Commission (NHC) has issued a set of guidelines aimed at strengthening clinical specialized department capacities. The goal is to establish a series of unique clinically specialized departments to cater to patients with serious diseases that have a high incidence rate. By the end of 2025, the NHC…
-
Nanjing Immunophage Biotech’s IPG11406 Approved for SLE Clinical Trial in China
•
Nanjing Immunophage Biotech Co., Ltd, a China-based biotechnology company, has announced that it has received clinical trial approval from the Center for Drug Evaluation (CDE) for its in-house developed Category 1 pipeline candidate, IPG11406. This small molecule is intended to be assessed as a treatment for systemic lupus erythematosus (SLE)…
-
Pyrotech (Beijing) Biotechnology Secures $97.37 Million in Series A Financing
•
China-based biotech firm Pyrotech (Beijing) Biotechnology Co., Ltd announced the successful completion of a CNY 700 million (USD 97.37 million) Series A financing round last week. The round was spearheaded by SDIC Venture Capital, with China Venture Capital Fund as a co-leader. New participants in this funding round included China…
